Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GLB1 | P16278 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9370557 | 0.91 | ALDH1A1 (0.47) | ALDH1A1SLC6A2HPGDCA2TAAR1 | |
| SCHEMBL20830104 | 0.91 | ALDH1A1 (0.47) | ALDH1A1SLC6A2HPGDCA2TAAR1 | |
| SCHEMBL9372158 | 0.90 | ALDH1A1 (0.47) | ALDH1A1PDE4DSLC6A2HPGDGLB1 | |
| SCHEMBL22333926 | 0.88 | ALDH1A1 (0.46) | ALDH1A1PDE4DSLC6A2HPGDGLB1 | |
| SCHEMBL29558404 | 0.88 | ALDH1A1 (0.46) | ALDH1A1PDE4DSLC6A2HPGDGLB1 | |
| SCHEMBL22333927 | 0.88 | ALDH1A1 (0.46) | ALDH1A1PDE4DSLC6A2HPGDGLB1 | |
| SCHEMBL4953659 | 0.83 | ALDH1A1 (0.69) | ALDH1A1SLC6A2HPGDKMT2ATACR2 | |
| SCHEMBL5470533 | 0.82 | HPGD (0.53) | ALDH1A1SLC6A2HPGDMEN1KMT2A | |
| SCHEMBL14414850 | 0.82 | HPGD (0.53) | ALDH1A1SLC6A2HPGDMEN1KMT2A | |
| SCHEMBL21756599 | 0.82 | HPGD (0.53) | ALDH1A1SLC6A2HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2023159930-A1 | COMPOUND FOR RNA CAPPING AND APPLICATION OF COMPOUND | 广州市恒诺康医药科技有限公司 | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | RNGTT, RNMT, NSUN2 | ALDH1A1 2179/4885PDE4D 1056/4885SLC6A2 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.